Emerging role of immune checkpoint inhibitors in recurrent and metastatic head and neck squamous cell carcinoma

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial2024 · 22 citations
2. 2Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations2024 · 93 citations
3. 3Penpulimab combined with anlotinib in patients with R/M HNSCC after failure of platinum-based chemotherapy: a single-arm, multicenter, phase Ⅱ study2023 · 15 citations
4. 4Mechanisms of Resistance and Therapeutic Perspectives in Immunotherapy for Advanced Head and Neck Cancers2024 · 31 citations
5. 5VISTA-mediated immune evasion in cancer2024 · 45 citations